These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16787685)

  • 21. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
    Dziadziuszko R; Siemiatkowska A; Limon J; Rzyman W; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
    J Thorac Oncol; 2007 Jan; 2(1):91-2. PubMed ID: 17410018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
    Ushiki A; Koizumi T; Kobayashi N; Kanda S; Yasuo M; Yamamoto H; Kubo K; Aoyagi D; Nakayama J
    Jpn J Clin Oncol; 2009 Apr; 39(4):267-70. PubMed ID: 19155283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
    Rosell R; Ichinose Y; Taron M; Sarries C; Queralt C; Mendez P; Sanchez JM; Nishiyama K; Moran T; Cirauqui B; Mate JL; Besse B; Reguart N; Perez M; Sanchez JJ
    Lung Cancer; 2005 Oct; 50(1):25-33. PubMed ID: 16011858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Mantha AJ; Hanson JE; Goss G; Lagarde AE; Lorimer IA; Dimitroulakos J
    Clin Cancer Res; 2005 Mar; 11(6):2398-407. PubMed ID: 15788691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.
    Miller VA; Hirsch FR; Johnson DH
    J Clin Oncol; 2005 May; 23(14):3288-93. PubMed ID: 15886316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
    Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
    J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
    Miller VA; Johnson DH; Krug LM; Pizzo B; Tyson L; Perez W; Krozely P; Sandler A; Carbone D; Heelan RT; Kris MG; Smith R; Ochs J
    J Clin Oncol; 2003 Jun; 21(11):2094-100. PubMed ID: 12775734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
    Pastorino U; Calabrò E; Tamborini E; Marchianò A; Orsenigo M; Fabbri A; Sozzi G; Novello S; De Marinis F
    J Thorac Oncol; 2009 Feb; 4(2):266-7. PubMed ID: 19179908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
    Gandara DR; West H; Chansky K; Davies AM; Lau DH; Crowley J; Gumerlock PH; Hirsch FR; Franklin WA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4205s-4209s. PubMed ID: 15217959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
    Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Noda K; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
    Am J Clin Pathol; 2007 Jul; 128(1):100-8. PubMed ID: 17580276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].
    Yuyama K; Matsushita H; Egawa K; Osawa T; Tsubouchi Y; Takahashi T; Miura H
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):433-5. PubMed ID: 22421774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
    West HL; Franklin WA; McCoy J; Gumerlock PH; Vance R; Lau DH; Chansky K; Crowley JJ; Gandara DR
    J Clin Oncol; 2006 Apr; 24(12):1807-13. PubMed ID: 16622257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple atypical adenomatous hyperplasia with synchronous multiple primary bronchioloalveolar carcinomas.
    Kishi K; Homma S; Kurosaki A; Tanaka S; Matsushita H; Nakata K
    Intern Med; 2002 Jun; 41(6):474-7. PubMed ID: 12135182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of a patient with synchronous advanced non-small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low-dose cytarabine and aclarubicin.
    Takigawa N; Takeuchi M; Shibayama T; Yoshida I; Kawata N; Tada A; Ueoka H; Takahashi K
    Anticancer Res; 2005; 25(3c):2579-82. PubMed ID: 16080496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gefitinib for advanced bronchioloalveolar carcinoma].
    Zhang XT; Wang SL; Li LY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):340-3. PubMed ID: 15266843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.
    Kitazaki T; Fukuda M; Soda H; Kohno S
    Lung Cancer; 2005 Jul; 49(1):125-8. PubMed ID: 15949598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe bronchorrhea in a patient with bronchioloalveolar carcinoma.
    Popat N; Raghavan N; McIvor RA
    Chest; 2012 Feb; 141(2):513-514. PubMed ID: 22315118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.